Mission
Mission
Mission, Texas, United States9 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D) | Cushing syndrome, Nutritional and Metabolic Diseases, Paraneoplastic Endocrine Syndromes, adrenal gland disorder, adrenal gland hyperfunction, diabetes mellitus, ectopic ACTH secretion syndrome, endocrine system disorder, glucose metabolism disease, metabolic disease, neoplasm, paraneoplastic syndrome, type 2 diabetes mellitus | Recruiting | Phase 2 | 2026-10-06 | NCT07296484 | |
| Deliver-EE: Evaluating Effects of Meal Delivery | Healthy | Active, not recruiting | Not applicable | 2026-10-02 | NCT05357261 | |
| MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study | bone disorder, lumbar spinal stenosis, musculoskeletal system disorder, spinal stenosis, vertebral column disorder | Recruiting | Not stated | 2026-09-30 | NCT03072927 | |
| A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutrition | Recruiting | Phase 3 | 2026-09-22 | NCT07392190 | |
| A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, nutritional disorder, obesity disorder, overnutrition, type 2 diabetes mellitus | Active, not recruiting | Phase 3 | 2026-07-31 | NCT06993792 | |
| A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutrition | Active, not recruiting | Phase 3 | 2026-07-29 | NCT06972459 | |
| A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, nutritional disorder, obesity disorder, overnutrition, type 2 diabetes mellitus | Active, not recruiting | Phase 3 | 2026-04-20 | NCT06972472 | |
| Efficacy of Fusidic Acid 1% in the Treatment of Bacterial Conjunctivitis | Bacterial Infections and Mycoses, Conjunctival Diseases, Eye Infections, Bacterial, Infections, bacterial conjunctivitis, bacterial infectious disease, conjunctivitis, eye disorder, eye infectious disorder | Recruiting | Phase 3 | 2026-03-17 | NCT06911424 | |
| SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study | Cardiovascular Abnormalities, Chronic Disease, Chronic Kidney Diseases, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Fistula, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, Vascular Fistula, arteriovenous hemangioma/malformation, cardiovascular disorder, chronic renal failure syndrome, congenital arteriovenous fistula, kidney disorder, kidney failure, urinary system disorder, vascular disorder, vascular malformation | Recruiting | Not applicable | 2026-02-17 | NCT06001827 |